Therapeutic Status of Neomycin in Hepatic Coma

Background: Rationale for Use

Hepatic coma (hepatic encephalopathy, HE) develops primarily because damaged or shunted liver tissue fails to convert portal-vein ammonia into urea. Ammonia generated by urease-producing coliform bacteria in the gut then accumulates in the systemic circulation and interferes with cerebral metabolism - particularly within astrocytes, which must detoxify it by forming glutamine at the cost of ATP.

Neomycin - a poorly absorbed oral aminoglycoside - was introduced precisely to break this cycle by suppressing urease-producing enteric flora and thereby reducing luminal ammonia production, - Adams and Victor's Principles of Neurology.

Mechanism of Action

Neomycin is given orally and acts locally within the gut lumen.
It reduces aerobic coliform flora (gram-negative organisms carrying urease).
This decreases the bacterial hydrolysis of nitrogenous substrates (undigested protein, urea) into ammonia.
The result is a fall in portal ammonia load and, in turn, a fall in arterial NH3.
It has little effect on anaerobes, so it is sometimes paired with lactulose for broader coverage of nitrogen metabolism, - Katzung's Basic and Clinical Pharmacology, 16th Ed.

Dosing (Historical/Current Reserve Use)

Indication	Dose
Acute/overt hepatic encephalopathy	1 g orally every 6-8 hours
Emergency / via NGT or rectal enema	250 mg every 6-12 hours (max 4 g/day)
Bowel preparation (pre-surgery, comparative context)	1 g every 6-8 h for 1-2 days

Rosen's Emergency Medicine specifies 250 mg PO q6-12h (max 4000 mg/day) when rifaximin cannot be used.

Efficacy Evidence

Several clinical trials have examined neomycin's effectiveness:

Neomycin vs lactulose (4 days): Equally effective, per RCT data cited in Mulholland & Greenfield's Surgery.
Neomycin vs metronidazole: Metronidazole for 7 days was as effective as neomycin.
Neomycin (10 days) for chronic HE: Equal to lactulose in one trial.
Neomycin + lactulose: Shown to be effective in combination, - Symptom to Diagnosis, 4th Ed.
Neomycin vs placebo: At least one RCT showed no significant difference.

A 2026 Cochrane systematic review (Jeyaraj et al., Cochrane 2026, PMID: 41631546) - the most current high-level evidence - analyzed 24 RCTs (1,405 participants, including 15 neomycin trials). The overall certainty of evidence for all comparisons was low to very low due to high risk of bias, imprecision, and heterogeneity. The review concluded that no aminoglycoside (including neomycin) could be firmly recommended over standard of care based on current evidence quality.

Current Therapeutic Status: Largely Supplanted

Neomycin is no longer first-line for hepatic encephalopathy in modern practice. It has been replaced for the following reasons:

Why Neomycin Fell Out of Favor

Problem	Detail
Ototoxicity	Auditory damage (more than vestibular), especially with prolonged use; may be irreversible
Nephrotoxicity	Risk of renal damage, particularly in patients with cirrhosis who already have impaired renal perfusion; relatively contraindicated in renal insufficiency
Systemic absorption	Despite being "poorly absorbed," enough can cross in patients with compromised gut mucosal integrity
RCT evidence	At least one trial showed no benefit over placebo

"Use of neomycin for hepatic encephalopathy has been largely supplanted by lactulose and other medications that are less toxic."

Katzung's Basic and Clinical Pharmacology, 16th Ed.

"The past use of oral neomycin carried a risk of renal damage and ototoxicity and has therefore been replaced by rifaximin."

Adams and Victor's Principles of Neurology, 12th Ed.

Current Position in Treatment Hierarchy

First-line:        Lactulose (osmotic cathartic + pH lowering + ammonia trapping)
Second-line:       Rifaximin + lactulose (preferred antibiotic - minimally absorbed, concentrates in GI tract, low systemic toxicity)
Reserve/adjunct:   Neomycin (when rifaximin is unavailable or contraindicated)
                   Metronidazole, vancomycin (less commonly used)

Lactulose targets both dietary and endogenous ammonia; titrated to produce 2-3 soft stools/day, - Symptom to Diagnosis, 4th Ed.
Rifaximin added to lactulose increases complete reversal of HE (76% vs 50.8%) and reduces mortality (23.1% vs 49.1%), - Mulholland & Greenfield's Surgery.
Neomycin is now reserved for patients unable to tolerate or with contraindications to rifaximin, - Rosen's Emergency Medicine.

Other Considerations

Protein restriction is no longer recommended - it increases mortality. Small, frequent meals with complex carbohydrates are preferred.
Complementary measures: zinc replacement (required for urea cycle enzymes), probiotics (non-urease-producing bacteria), H. pylori eradication.
L-ornithine L-aspartate (LOLA) lowers postprandial ammonia and is used in some settings.
Liver transplantation remains the definitive treatment for refractory hepatic encephalopathy.
In obtunded patients, both lactulose and neomycin can be given via nasogastric tube or rectal enema, - Rosen's Emergency Medicine.

Summary

Neomycin was historically one of the few effective agents in hepatic coma, directly targeting the gut flora responsible for ammonia generation. Its efficacy is comparable to lactulose in short-term RCTs. However, its risks of irreversible ototoxicity and nephrotoxicity - particularly dangerous in the cirrhotic population with baseline renal compromise - have led to it being largely abandoned in favor of rifaximin, which achieves the same antibacterial effect in the gut with far less systemic toxicity. Neomycin retains a niche role as a reserve agent when preferred options are unavailable.

This is a shared conversation. Sign in to Orris to start your own chat.